Provided by Tiger Trade Technology Pte. Ltd.

Alpha Tau Medical

7.36
-0.3500-4.54%
Pre-market: 7.360.00000.00%08:00 EST
Volume:453.03K
Turnover:3.33M
Market Cap:627.54M
PE:-14.10
High:7.77
Open:7.77
Low:7.14
Close:7.71
52wk High:7.89
52wk Low:2.30
Shares:85.26M
Float Shares:57.13M
Volume Ratio:1.31
T/O Rate:0.79%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5219
EPS(LYR):-0.4540
ROE:-54.38%
ROA:-25.56%
PB:8.09
PE(LYR):-16.21

Loading ...

Alpha Tau issues letter to shareholders

TIPRANKS
·
Jan 29

Alpha Tau Medical Ltd - Ramping U.S. Manufacturing for Commercial Readiness

THOMSON REUTERS
·
Jan 29

Alpha Tau Medical Ltd. Publishes Shareholder Letter Covering Fiscal Year 2025

Reuters
·
Jan 29

BRIEF-Alpha Tau Reports New Positive Results In Two Upcoming Presentations

Reuters
·
Jan 06

Alpha Tau Medical Reports 81% Disease Control Rate in Pancreatic Cancer Alpha DaRT Study

Reuters
·
Jan 06

Alpha Tau Reports New Positive Results in Two Upcoming Presentations at Asco Gi 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha Dart® Study

THOMSON REUTERS
·
Jan 06

BRIEF-Alpha Tau Submits First Pre-Market Approval Module To The FDA

Reuters
·
Jan 05

FDA Begins Modular Review of Alpha Tau’s Alpha DaRT for Recurrent cSCC

Reuters
·
Jan 05

Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha Dart® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (Cscc)

THOMSON REUTERS
·
Jan 05

Alpha Tau Medical to Present Corporate Update at J.P. Morgan Healthcare Conference

Reuters
·
Dec 18, 2025

Is Alpha Tau Medical (NASDAQ:DRTS) Using Debt Sensibly?

Simply Wall St.
·
Dec 11, 2025

Alpha Tau Medical Up Over 12%, on Track for Highest Close Since January 2023 -- Data Talk

Dow Jones
·
Dec 11, 2025

Alpha Tau Medical Is Maintained at Buy by Citigroup

Dow Jones
·
Dec 11, 2025

Alpha Tau Medical Ltd - Treats First Patient in Glioblastoma Study

THOMSON REUTERS
·
Dec 09, 2025

Alpha Tau Medical Treats First Glioblastoma Patient with Alpha DaRT in U.S. Trial

Reuters
·
Dec 09, 2025

Alpha Tau Medical Launches U.S. Clinical Trial of Alpha DaRT for Pancreatic Cancer

Reuters
·
Dec 04, 2025

Alpha Tau Medical Wins FDA Approval to Begin Prostate Cancer Trial

Reuters
·
Dec 02, 2025

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients With Locally Recurrent Prostate Cancer

THOMSON REUTERS
·
Dec 02, 2025

Alpha Tau to Participate in December Investor Conferences

GlobeNewswire
·
Dec 01, 2025

Alpha Tau Medical Price Target Maintained With a $9.00/Share by HC Wainwright & Co.

Dow Jones
·
Nov 24, 2025